Skip to main content
Non-transfusion-dependent thalassemias.
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.
Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements.
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.